Literature DB >> 7667388

Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue.

R Corbett1.   

Abstract

The noncompetitive N-methyl-D-aspartate (NMDA) antagonist dizocilpine (MK-801) produced an interoceptive stimulus cue in rats trained to discriminate between MK-801 (0.075 mg/kg) and saline in a two-choice, discrete trial avoidance paradigm. Haloperidol (0.03-0.3 mg/kg) failed to antagonize the discriminative stimulus cue of MK-801, with all rats choosing the MK-801-appropriate choice lever. Higher doses of haloperidol (1.0 mg/kg) produced significant sedation such that the rats were unable to complete all the trials. In contrast, clozapine dose dependently antagoinzed the discriminative stimulus cue produced by MK-801. Clozapine at a dose of 3.0 mg/kg completely antagonized the stimulus cue produced by MK-801. Therefore, the discriminative stimulus cue produced by the noncompetitive NMDA antagonist MK-801 may be useful as an animal model for selecting novel drugs with potential efficacy for treatment-resistant schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667388     DOI: 10.1016/0091-3057(95)00072-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Acute N-methyl-D-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats.

Authors:  I Feinstein; M F Kritzer
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

2.  Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus.

Authors:  Jennifer E Murray; Rick A Bevins
Journal:  Eur J Pharmacol       Date:  2007-02-01       Impact factor: 4.432

3.  Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats.

Authors:  L Paulson; P Martin; E Ljung; K Blennow; P Davidsson
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.